Our history

Foundation of Biotest Serum-Institut GmbH by Carl Adolf Schleussner and Dr. Hans Schleussner.
Initially the family enterprise focussed on research on blood typing serology.
The test serum anti-D for the determination of the rhesus factor is introduced world-wide as one of the first products of this kind.
Production of the first plasma protein product, Biseko® 
Groundbreaking for the new production facilities at Dreieich. Follwed by gradual transfer of all activities from Frankfurt to Dreieich.
Foundation of first European distribution subsidiaries in Italy and Austria.
Production of the first polyspecific immunoglobulin preparation


Foundation of distribution subsidiary in U.K.
Development of the first air sampler as the start of Biotest's Microbiological Diagnostic business
(hygiene monitoring)
1982 and 1983
Market introduction of the hyper-immunoglobulin preparations Hepatect®, Cytotect®, and Varitect®


  • Market introduction of the first intravenously tolerable IgM-enriched immunoglobulin Pentaglobin®
  • Foundation of distribution subsidiary in Switzerland


Reorganization of Biotest Serum-Institut GmbH to Biotest AG, advancing the expansion of the business divisions Pharmaceuticals and Diagnostics.


As a world-wide operating corporation, Biotest goes public on the Frankfurt Stock Exchange.

Foundation of distribution subsidiary in Hungary


Production of the first double virus-inactivated factor VIII preparation (Haemoctin®) for hemophiliacs

Foundation of the German plasma collection company Plasma Service Europe GmbH


  • Start of operation of the extensively modernized pharmaceutical production facilty, followed by further additions to capacity (total investments over € 80 million)
  • Market introduction of Intratect®


Approval of the fully automated blood typing system TANGO and the corresponding reagents for the US market


  • Purchase of plasma protein business of Nabi Biopharmaceuticals Corp.
  • Biotest preference share listed in SDAX  


  • Foundation of the Hungarian plasma collection company Plazmaszolgálat Kft.
  • FDA authorises marketing of manual reagents for blood group typing
  • European approval for Haemonine® (Factor IX)



  • Expansion of immunoglobulin production capacity at the Dreieich site from 2 to 4 tons
  • Marketing authorization for Zutectra®
  • Sale of Medical Diagnostics business to Bio-Rad completed
  • Foundation of distribution subsidiary in Spain
  • Cooperation contract on co-development and co-marketing of monoclonal antibody BT-061 with Abbott Laboratories, Inc.
  • Sale of microbiological monitoring business to Merck KGaA
  • Foundation of distribution subsidiary in Brazil
  • Europe-wide marketing authorization of Intratect® 100 g/l (10%)
  • Marketing authorization Bivigam® in the US





  • Strategic long-term contract and licensing agreement with AMDA
  • New distribution agreement in Russia with Merz Pharma, (Frankfurt, Germany), and in Greece with Vianex s.a.
  • Market launch of Bivigam® in the US
  • New share issuance successfully secures € 76 million capital increase
  • Biotest support "project recovery" for the production of haemophilia preparations for developing countries 
  • Private debt placement rises € 210 million
  • Market authorization of Albiomin® in Brazil, commissioning of the extended Albiomin®  production capacity
  • Start of the expansion projekt "Biotest Next Level" at the Dreieich site in Germany
  • Marketing authorization Albiomin in China
  • Foundation of distribution subsidiary in France
  • Biotest share split becomes effective on July 15 with the ratio 1:3
  • Opening of day care center
  • Start of clinical phase IIa trial with the monoclonal antibody BT-063 in the indication Systemic Lupus Erythematosus (SLE)
  • Commissioning of new Plasma goods receipt area including Virological test laboratories
  • Biotest opens six additional plasma collection centers: four in the US and two in Hungary
  • Cooperation agreement with Octapharma for German-speaking markets to offer a recombinant factor VIII preparation
  • Start of global clinical phase III study of IgG Next Generation in the indication Primary Immunodeficiency Disease (PID), a novel development of our polyvalent immunoglobulin G
  • Sale of US-Therapy business of Biotest Pharmaceuticals Corp. to ADMA Biologics with at the same time intensified cooperation with ADMA
  • Start of European clinical phase III study in the indication Primary Immune Thrombocytopenia (ITP) of IgG Next Generation, a novel development of our polyvalent immunoglobulin G